TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03336983
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide in the presence or absence of Zoledronic Acid
Study: NCT00122850
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00669955
Drug: Omeprazole, amoxicillin, clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID
Study: NCT00235859
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00231296
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management- treatment with standard medical therapy, which includes anti-arrhythmic medications
Study: NCT02468557
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m\^2) or racemic leucovorin 400 mg/m\^2, oxaliplatin 85 mg/m\^2, bolus 5-fluorouracil 400 mg/m\^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m\^2.
Study: NCT00770003
Drug: AZD8848
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month
Study: NCT00770003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal spray solution. Once weekly intranasal administrations for one month.
Study: NCT01393990
Drug: LY2228820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02919475
Drug: JTE-051
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug tablets containing JTE-051
Study: NCT02919475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets identical in appearance to the active drug tablets
Study: NCT02123056
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
Study: NCT01594723
Drug: 120 mg LY2784544
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02688140
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02688140
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02688140
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02720952
Drug: Infacort®
Approvals — FDA: no, EMA: no, PMDA: no
Description: dry granule formulation of hydrocortisone
Study: NCT01080027
Drug: Rebif® New Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recommended dose of Rebif® is 22 or 44 μg administered three times per week by subcutaneous injection.
Study: NCT00830674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose IV or SC administration
Study: NCT01011322
Drug: LT-02
Normalized name: LT KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks
Study: NCT01011322
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00916890
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal fentanyl will be randomly assigned to a patient.
Study: NCT01200862
Drug: Investigational new drug company code: BGS649
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01200862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01461083
Drug: [18F]MPPF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed by intravenous bolus injection of \[18F\]MPPF targeted to be 5.0 mCi, and not to exceed 5.5 mCi (not \>10% of 5.0 mCi limit) and not to exceed 5 µg of MPPF
Study: NCT00720798
Drug: Disease-modifying anti-rheumatic drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These drugs could be used alone or in combination, except for the combination of methotrexate and leflunomide, which was not allowed.
Study: NCT00720798
Drug: Non-steroidal anti-inflammatory drugs
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants could be treated with non-steroidal anti-inflammatory drugs up to the maximum recommended dose throughout the study. The choice and doses of non-steroidal anti-inflammatory drugs were at the discretion of the investigator.
Study: NCT00720798
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (≤ 10 mg/day) were permitted during the study.
Study: NCT02448810
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Investigator's choice~* Dose according to drug label
Study: NCT00096083
Drug: isolated perfusion
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01438723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: prior to CABG surgery 3 day treatment with placebo capsules three times a day
Study: NCT04469075
Drug: Clindamycin Phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: phosphate 1% solution triamcinolone 0.01% at every array change (or approved equivalent)
Study: NCT00975637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SC
Study: NCT01519609
Drug: bowel prep before endoscopy
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bowel prep before colonoscopy
Study: NCT00198497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00835822
Drug: Venocur Triplex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
Study: NCT00835822
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
Study: NCT00532155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
Study: NCT01084005
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive placebo matching linagliptin 5 mg once daily
Study: NCT00600288
Drug: Non-preserved saline solution (Placebo)
Normalized name: CONTACT LENS SALINE,PRESERVED
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 drops administered in each eye 4 times a day for 6 weeks
Study: NCT02322021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
Study: NCT03552458
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be identical in physical appearance and color to the study agent and will be made by the manufacturer
Study: NCT00401882
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine (1 mg) IV additional doses
Study: NCT03974594
Drug: Trifluridine and Tipiracil Tablets
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine and Tipiracil Tablets given 20mg orally once under fasting or postprandial conditions per cycle
Study: NCT04558684
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPOX (6 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine: Dose of 2000mg/m2,14 days, q3w
Study: NCT04558684
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab (6 cycles): 200mg on day 1 of each cycle, q3w
Study: NCT01021579
Drug: Metfomin plus Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03276988
Drug: Period 1 GX-30, Period 2 THYROGEN®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B - Sequence A. GX-30 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, THYROGEN® 0.9mg will be administered in Period 2.
Study: NCT03276988
Drug: Period 1 THYROGEN®, Period 2 GX-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B - Sequence B. THYROGEN® 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, GX-30 0.9mg will be administered in Period 2.
Study: NCT02244437
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02244437
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02367053
Drug: ZP4207
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02011594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT00368537
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours)
Study: NCT00685919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 6 hours for 5 doses, given orally, and matching Carbidopa
Study: NCT03452228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by Intravenous (IV)
Study: NCT00006170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matched placebo pill
Study: NCT01783106
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: experimental
Study: NCT00322101
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00322101
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01590433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will inject 5mcg of identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
Study: NCT03818737
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The corticosteroid injection is prepared by mixing 1cc of 40mg/dL depomedrol and 6cc of normal saline in a 10cc syringe will be made into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
Study: NCT01090973
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.~After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses.
Study: NCT02284360
Drug: APOSEC™ for cutaneous use
Approvals — FDA: no, EMA: no, PMDA: no
Description: On day 0, a blinded and randomized test treatment with Verum and Placebo is performed on intact skin. If the subject does not reveal any adverse events, the actual treatment phase is initiated 24h later.~Following baseline evaluation on day 1, two punch biopsies (4mm) on the inner upper side of the non-dominant arm are set under local anesthesia. One wound on the upper arm (proximal or distal) will be treated with placebo and the second wound will be treated with the allocated concentration of Verum according to previous randomization scheme set for test treatment. Approximately 1ml of Verum vs. placebo will be applied on the artificial wounds.~From day 2 to 6, artificial wounds will be cleaned with 0.9 % NaCl and then allocated treatment will be administered. Wound dressing will be done daily and will cover the whole area of application.~On day 7 the treatment is terminated and the wound is evaluated with respect the extension of wound closure.
Study: NCT01990885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00497471
Drug: iron (2 mg/kg/daily)
Normalized name: Iron(2+) fumarate
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01602380
Drug: faslodex dummy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
Study: NCT01602380
Drug: arimidex dummy
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet 1 daily
Study: NCT01717456
Drug: Laxatives or anti-diarrheals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miralax at a dose of one packet (17 grams) daily may be used for constipation if unresponsive to fiber. Dose may be titrated up to two packets (34 grams) daily if needed.~Imodium at a starting dose of 2 mg/day may be used for diarrhea if unresponsive to fiber. Dose of Imodium may be titrated down to 1 mg or up to 4 mg if needed.
Study: NCT03753269
Drug: Placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15ml 0.9% saline will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
Study: NCT03802227
Drug: NKTR-181
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination of NKTR-181 and oxycodone IR placebo
Study: NCT00891683
Drug: AEG33773 oral dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
Study: NCT03770871
Drug: Indirect pulp treatment using Vitrebond (TM )
Normalized name: acai fruit pulp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial caries removal and protection of the dental pulp with biocompatible material
Study: NCT02370706
Drug: PIM447
Approvals — FDA: no, EMA: no, PMDA: no
Description: pan-pim inhibitor
Study: NCT02370706
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitor
Study: NCT00239902
Drug: FTY720
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02269748
Drug: Analgesic Therapy
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg TID
Study: NCT03608371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule matching BTRX-246040 40 mg capsule
Study: NCT04514029
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40 mg started 2 weeks (+/-5 days) prior to apheresis through day +30
Study: NCT00479310
Drug: Summers 5% L.A.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00503516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 sachet of 160 mg of placebo b.i.d.
Study: NCT00954304
Drug: HM30181AK 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181AK 1mg tablet
Study: NCT00954304
Drug: HM30181AK 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181AK 5mg tablet
Study: NCT00954304
Drug: HM30181AK 15mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181AK 15mg tablet
Study: NCT00954304
Drug: HM30181AK 60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181AK 60mg tablet
Study: NCT03819153
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are to inject placebo (semaglutide) with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject placebo (semaglutide) under their skin. Participants will inject placebo (semaglutide) 1 time a week on the same day of the week. Participants' dose of placebo (semaglutide) will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
Study: NCT03094403
Drug: Finacea® (azelaic acid) Gel, 15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel
Study: NCT03094403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel
Study: NCT00090168
Drug: MK0653A , ezetimibe (+) simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00090168
Drug: Duration of Treatment: 6 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02275988
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01632046
Drug: lactate and bicarbonate buffered dialysis solutions
Normalized name: lactate Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either PD-solution will be applied. Number of cycles and glucose concentration will be varied according to clinical needs. Sleep Safe system will be used and connected to Sleep Safe Cyclers in patient on CCPD.
Study: NCT00634400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02555709
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 matching VTP-43742 administered as an oral capsule once daily
Study: NCT00691002
Drug: Calcipotriol plus hydrocortisone (LEO 80190)
Normalized name: hydrocortisone Rectal Cream [Recort Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application
Study: NCT00691002
Drug: LEO 80190 Vehicle
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00691002
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02555709
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 matching VTP-43742 administered as an oral capsule once daily
Study: NCT02616562
Drug: Norditropin® FlexPro® pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) once daily.
Study: NCT02545413
Drug: Probiotic VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05074589
Drug: Irinotecan liposome、5-Fluorouracil、Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan liposome、5-Fluorouracil、Leucovorin
Study: NCT05074589
Drug: Placebo、5-Fluorouracil、Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo、5-Fluorouracil、Leucovorin
Study: NCT00962299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once a day by metered dose inhaler with spacer for 6 months
Study: NCT00854009
Drug: BLI-489
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00854009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00664469
Drug: Comparator: Simvastatin 20, 40 and 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20, 40 and 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
Study: NCT00664469
Drug: Comparator: Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10, 20 \& 40 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
Study: NCT02595333
Drug: Group SF1
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
Study: NCT02595333
Drug: Group S1
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil was administered for analgesia in primary cesarean section
Study: NCT02595333
Drug: Group SF2
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil and flurbiprofen was administered for analgesia in repeated cesarean section
Study: NCT00610623
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/day, IV from day 1 to 20
Study: NCT00610623
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once per day, IV from day 1 to 20
Study: NCT02595333
Drug: Group S2
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil was administered for analgesia in repeated cesarean section
Study: NCT01154153
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.
Study: NCT01154153
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment assignment was randomized with stratification by sex and age group (\>=2 to \<6, \>=6 to \<12 years old).~* For children who were \>=2 to \<6 years old, 1 spray/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.~* For children who were \>= 6 yrs to \<12 years old, either 1 spray/nostril or 2 sprays/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.
Study: NCT01154153
Drug: Claritin® Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children's Claritin® Syrup \[5 mg of loratadine per 5 mL\] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
Study: NCT02152787
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00359437
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration once daily